These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30511350)

  • 41. Predictors of noncompliance in patients with schizophrenia.
    Perkins DO
    J Clin Psychiatry; 2002 Dec; 63(12):1121-8. PubMed ID: 12523871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
    Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
    Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subjective well-being of patients with schizophrenia as a target of drug treatment.
    Karamatskos E; Mulert C; Lambert M; Naber D
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1490-9. PubMed ID: 22283757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications.
    de Haan L; Lavalaye J; van Bruggen M; van Nimwegen L; Booij J; van Amelsvoort T; Linszen D
    Can J Psychiatry; 2004 May; 49(5):290-6. PubMed ID: 15198464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
    Awad AG
    J Psychopharmacol; 2012 Jul; 26(7):953-7. PubMed ID: 22170735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia.
    Kaneda Y
    Clin Neuropharmacol; 2003; 26(4):182-4. PubMed ID: 12897637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Relationships between positive or negative early subjective response to antipsychotics and demographic and clinical variables in the group of patients with schizophrenia].
    Murawiec S
    Psychiatr Pol; 2005; 39(6):1185-98. PubMed ID: 16526184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team.
    Seshadri M; Elsemary A; Thalitaya MD; Chikodzore L; Nagalingam P
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):524-529. PubMed ID: 28953820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up Study.
    Glick ID; Davis JM; Zamora D; Ballon J; Nuthi M
    J Clin Psychopharmacol; 2017 Apr; 37(2):125-130. PubMed ID: 28195931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
    Owens DG
    Drugs; 1996 Jun; 51(6):895-930. PubMed ID: 8736614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clozapine versus typical neuroleptic medication for schizophrenia.
    Wahlbeck K; Cheine M; Essali MA
    Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.
    Sağlam Aykut D
    J Clin Psychopharmacol; 2019; 39(1):57-62. PubMed ID: 30566417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subjective well-being under the neuroleptic treatment and its relevance for compliance.
    Naber D; Karow A; Lambert M
    Acta Psychiatr Scand Suppl; 2005; (427):29-34. PubMed ID: 15943008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.